Wheatley-Price, Paul <br/><br/>
Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  May 2008 
 - 2350-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2007.15.2280  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Age Factors<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--adverse effects<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Double-Blind Method<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Middle Aged<br/>Protein Kinase Inhibitors--adverse effects<br/>Quality of Life<br/>Quinazolines--adverse effects<br/>Retrospective Studies